SGRY VS MRTX Stock Comparison

PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatility
PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatility

Performance

SGRY
10/100

SGRY returned 4.97% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

MRTX
10/100

MRTX returned -20.64% in the last 12 months. Based on SPY's performance of -13.86%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

SGRY
61/100

9 analysts offer 12-month price targets for SGRY. Together, they have an average target of 64, the most optimistic target put SGRY at 64 within 12-months and the most pessimistic has SGRY at 64.

MRTX
85/100

5 analysts offer 12-month price targets for MRTX. Together, they have an average target of 102.1, the most optimistic target put MRTX at 247 within 12-months and the most pessimistic has MRTX at 53.

Technicals

SGRY
64/100

SGRY receives a 64 of 100 based on 14 indicators. 8 are bullish, 4 are bearish.

MRTX
86/100

MRTX receives a 85 of 100 based on 14 indicators. 11 are bullish, 1 are bearish.

Earnings

SGRY
10/100

SGRY has missed earnings 11 times in the last 20 quarters.

MRTX
10/100

MRTX has missed earnings 8 times in the last 20 quarters.

Profit

SGRY
61/100

Out of the last 20 quarters, SGRY has had 14 profitable quarters and has increased their profits year over year on 7 of them.

MRTX
10/100

Out of the last 20 quarters, MRTX has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

SGRY
47/100

SGRY has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

MRTX
67/100

MRTX has had a higher than average amount of volatility over the last 12 months giving it a score of 66 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Surgery Partners, Inc. Common Stock Summary

Nasdaq / SGRY
Healthcare
Medical - Care Facilities
Surgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company operates through two segments, Surgical Facility Services and Ancillary Services. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management. The company's surgical hospitals also provide ancillary services, such as diagnostic imaging, pharmacy, laboratory, obstetrics, oncology, physical therapy, and wound care; and ancillary services, which consist of multi-specialty physician practices, urgent care facilities, and anesthesia services. As of December 31, 2021, it owned or operated a portfolio of 126 surgical facilities, including 108 ambulatory surgical centers and 18 surgical hospitals in 31 states. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.

Mirati Therapeutics, Inc. Common Stock Summary

Nasdaq / MRTX
Healthcare
Biotechnology
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.